'Bi­ased and mis­lead­ing': No holds barred in FDA's sta­tis­ti­cal re­view of Bio­gen's Aduhelm

4 years ago
R&D
FDA+

Alzheimer's gold rush in­spires $565M deal be­tween Chi­nese phar­ma pow­er­house and lit­tle Ger­man biotech

4 years ago
Deals

Covid-19 roundup: Mod­er­na vac­cine kicks up an­ti­bod­ies against Delta vari­ant; UK study val­i­dates mix-and-match ...

4 years ago
Coronavirus

Mod­er­na hires a chief brand of­fi­cer to guide vac­cine cam­paigns through 'time of rapid growth'

4 years ago
People

At biotech's small­est com­pa­nies, fe­male ex­ec­u­tives make up on­ly a frac­tion of C-suite lead­ers — re­port

4 years ago
People

Sanofi in­vests in the fu­ture of mR­NA with plan to pump bil­lions of dol­lars in­to next-gen cell ther­a­py busi­ness

4 years ago
R&D
Cell/Gene Tx

Eras­ing can­cer, re­viv­ing on­colyt­ic virus, treat­ing a rare neu­ro­mus­cu­lar con­di­tion: Here's what you need to know about ...

4 years ago
Financing

Sanofi kicks off PhII test for RIPK1 in­hibitor, trig­ger­ing De­nali mile­stone; Ital­ian biotech flops key end­point in ...

4 years ago
News Briefing

Or­p­hazyme plans to lay off most of its staff fol­low­ing a string of fail­ures for lead 'pipeline-in-a-pro­duc­t'

4 years ago
People

As­traZeneca CEO Pas­cal So­ri­ot taps vet­er­an can­cer re­searcher Su­san Gal­braith for top on­col­o­gy post

4 years ago
People

Con­tro­ver­sial an­ti-ag­ing sci­en­tist — backed by Har­vard's George Church — makes a fresh round of claims on life ...

4 years ago
R&D
Discovery

Gilead­'s Kite earns sec­ond-line win for CAR-T Yescar­ta, set­ting up a bat­tle over ear­li­er blood can­cer pa­tients

4 years ago
R&D
Pharma

Ex­elix­is posts mixed re­sults for Cabome­tyx com­bo in ear­ly liv­er can­cer pa­tients, cast­ing doubt on piv­otal read­out

4 years ago
R&D

Covid-19 roundup: Sci­en­tists find long-last­ing re­sults from mR­NA vac­cines; As­traZeneca back on track for vac­cine ...

4 years ago
Coronavirus

Sanofi, As­traZeneca mark big leap to­ward fil­ing of RSV drug in 2022, with safe­ty da­ta in hand to chal­lenge Synagis

4 years ago
R&D

Polyphor mulls fu­ture af­ter PhI­II can­cer pro­gram crash­es

4 years ago
R&D

J&J choos­es an ad­vo­cate of the “gold­en age” of vac­cines at the Gates Foun­da­tion to lead the pipeline in­to the ...

4 years ago
Coronavirus

Hit­ting land­mark mile­stone, In­tel­lia shows CRISPR can ed­it genes di­rect­ly in pa­tients

4 years ago
R&D
Cell/Gene Tx

The FDA has now poked a hor­net's nest of con­tro­ver­sy in the House. And that could sting Bio­gen's mega block­buster ...

4 years ago
Bioregnum
FDA+

Are 'plat­form plays' here to stay?; The Aduhelm saga con­tin­ues to un­fold; A new GSK?; and more

4 years ago
Weekly

Af­ter years of fail­ure, Vi­a­Cyte shows off first proof-of-con­cept for di­a­betes stem cell trans­plants

4 years ago
R&D

EU reg­u­la­to­ry com­mit­tee rec­om­mends 8 new drugs for ap­proval, in­clud­ing Bris­tol My­er­s' BC­MA CAR-T

4 years ago
FDA+

US paus­es use of Eli Lil­ly's Covid-19 treat­ment na­tion­wide due to vari­ants

4 years ago
FDA+
Coronavirus

ACIP unan­i­mous­ly rec­om­mends Deng­vax­ia use, with same caveats as FDA la­bel; Chi­nese 3D print­ing com­pa­ny with ...

4 years ago
News Briefing
First page Previous page 688689690691692693694 Next page Last page
A service from the Financial Times